Brii Biosciences develops first-in-class therapies utilizing RNA interference and other biotechnological methods to treat infectious diseases and central nervous system disorders. The company focuses on addressing high unmet medical needs in patient populations facing limited treatment options and social stigmas.
Funding
$155M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IFounders
Product
Problem
Many patients with infectious diseases and central nervous system disorders face limited treatment options, high unmet medical needs, and social stigmas. Current therapies may be inadequate or nonexistent, leaving substantial gaps in patient care.
Solution
Brii Biosciences develops innovative therapies for infectious diseases and central nervous system disorders, focusing on areas with significant unmet medical needs. The company utilizes RNA interference (RNAi) and other biotechnological methods to create first-in-class and differentiated treatment options. By addressing these critical areas, Brii Biosciences aims to improve patient outcomes and tackle public health challenges.
Target Audience
The primary target audience includes patients suffering from infectious diseases and central nervous system disorders, as well as healthcare providers seeking advanced treatment options for these conditions.
Features
- Development of therapies for infectious diseases.
- Development of therapies for central nervous system disorders.
- Utilization of RNA interference (RNAi) technology.
- Focus on first-in-class and differentiated treatment options.